0 332

Cited 39 times in

Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer

Authors
 Sun-Young Kong  ;  Mi Hwa Han  ;  Heon-Jong Yoo  ;  Jong Ha Hwang  ;  Myong Cheol Lim  ;  Sang-Soo Seo  ;  Chong-Woo Yoo  ;  Jae-Hoon Kim  ;  Sang-Yoon Park  ;  Sokbom Kang 
Citation
 ANNALS OF SURGICAL ONCOLOGY, Vol.19(5) : 1707-1712, 2012 
Journal Title
ANNALS OF SURGICAL ONCOLOGY
ISSN
 1068-9265 
Issue Date
2012
MeSH
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor/blood* ; CA-125 Antigen/blood ; Carboplatin/administration & dosage ; Cohort Studies ; Disease-Free Survival ; Female ; Humans ; Middle Aged ; Multivariate Analysis ; Neoplasm Grading ; Neoplasm Staging ; Neoplasms, Glandular and Epithelial/blood* ; Neoplasms, Glandular and Epithelial/drug therapy ; Neoplasms, Glandular and Epithelial/pathology* ; Ovarian Neoplasms/blood* ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/pathology* ; Paclitaxel/administration & dosage ; Prognosis ; Proteins/analysis* ; Serum
Abstract
Background : This study was designed to determine whether serum HE4 is an independent prognostic factor in ovarian cancer patients.

Methods : We measured HE4 in pretreatment serum samples from 80 women with epithelial ovarian cancer, using an enzyme-linked immunosorbent assay. The results were correlated with clinical data.

Results : The median serum HE4 level in ovarian cancer patients was 98.7 (range, 80.3-222.8) pg/ml. Elevated serum HE4 levels before therapy significantly correlated with a poorer progression free survival (log-rank test, P = 0.017). Multivariate analysis revealed serum HE4 to be an independent prognostic factor for progression-free survival (P = 0.036). In multivariate regression analysis, high serum HE4 levels significantly correlated with high tumor grade and serous histology (P = 0.004 and 0.017). In addition, high serum HE4 levels were significantly associated with residual tumor size and operative time (P = 0.003 and 0.033).

Conclusions : Pretreatment serum HE4 seems to be an additional factor for predicting the outcome of patients with epithelial ovarian cancer. Due to its independence from established prognostic factors, serum HE4 may provide additional prognostic information.
Full Text
https://link.springer.com/article/10.1245/s10434-011-1943-5
DOI
10.1245/s10434-011-1943-5
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Obstetrics and Gynecology (산부인과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jae Hoon(김재훈) ORCID logo https://orcid.org/0000-0001-6599-7065
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/158268
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links